Polatuzumab Vedotin
drugOn this page
Also known as ACD-79B-VCMMAEACD-79BVCMMAEACD79B-VCMMAEAnti-cd79b adcDCDS-4501ADCDS4501AFCU-2711FCU2711Polatuzumab vedotin piiqPolatuzumab vedotin-piiqPolatuzumab vedotinaPolatuzumab vedotinePolivyRG-7596RG7596RO-5541077000
Summary
Polatuzumab Vedotin (CHEMBL3301582) is an approved antibody drug conjugate (ATC L01FX14) targeting CD79B; indicated across 12 conditions including diffuse large b-cell lymphoma and neoplasm.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody drug conjugate
- ATC class: L01FX14
- Targets: 1 (CD79B)
- Indications: 12 conditions
- Clinical trials: 65
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3301582 |
| Name | Polatuzumab Vedotin |
| Type | Antibody drug conjugate |
| Max phase | 4 |
| ATC | L01FX14 |
Also known as: ACD-79B-VCMMAE, ACD-79BVCMMAE, ACD79B-VCMMAE, Anti-cd79b adc, DCDS-4501A, DCDS4501A, FCU-2711, FCU2711, Polatuzumab vedotin, Polatuzumab vedotin piiq, Polatuzumab vedotin-piiq, Polatuzumab vedotina
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| CD79B | CD79B | Binding | 2.1% | P40259 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): CD79B.
Top Reactome pathways
10 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Adaptive Immune System | 1 | CD79B |
| Disease | 1 | CD79B |
| Immune System | 1 | CD79B |
| Infectious disease | 1 | CD79B |
| CD22 mediated BCR regulation | 1 | CD79B |
| Potential therapeutics for SARS | 1 | CD79B |
| SARS-CoV Infections | 1 | CD79B |
| Viral Infection Pathways | 1 | CD79B |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 1 | CD79B |
| Signaling by the B Cell Receptor (BCR) | 1 | CD79B |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| adaptive immune response | 1 |
| immune response | 1 |
| signal transduction | 1 |
| response to bacterium | 1 |
| B cell differentiation | 1 |
| B cell receptor signaling pathway | 1 |
| immune system process | 1 |
| cell surface receptor signaling pathway | 1 |
Indications & clinical
Indications
12 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| diffuse large B-cell lymphoma | 4 | MONDO:0018905 | EFO:0000403 |
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| B-cell neoplasm | 4 | MONDO:0004095 | MONDO:0004095 |
| B-cell non-Hodgkin lymphoma | 4 | MONDO:0015759 | EFO:1001938 |
| non-Hodgkin lymphoma | 3 | MONDO:0018908 | EFO:0005952 |
| neoplasm of mature B-cells | 2 | MONDO:0004949 | EFO:0000096 |
| follicular lymphoma | 2 | MONDO:0018906 | MONDO:0018906 |
| mantle cell lymphoma | 2 | MONDO:0018876 | EFO:1001469 |
| MALT lymphoma | 2 | MONDO:0007650 | EFO:0000191 |
| marginal zone lymphoma | 2 | MONDO:0017604 | EFO:1000630 |
| B-cell chronic lymphocytic leukemia | 1 | MONDO:0004948 | EFO:0000095 |
| lymphoma | 1 | MONDO:0005062 | EFO:0000574 |
Clinical trials
Total trials: 65.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 32 |
| PHASE1/PHASE2 | 16 |
| PHASE1 | 9 |
| PHASE3 | 6 |
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04833114 | PHASE3 | ACTIVE_NOT_RECRUITING | Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) |
| NCT05171647 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma |
| NCT06047080 | PHASE3 | ACTIVE_NOT_RECRUITING | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma |
| NCT03274492 | PHASE3 | COMPLETED | A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma |
| NCT04182204 | PHASE3 | COMPLETED | A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| NCT04236141 | PHASE3 | TERMINATED | A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). |
| NCT03533283 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma |
| NCT03671018 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma |
| NCT04479267 | PHASE2 | ACTIVE_NOT_RECRUITING | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma |
| NCT04491370 | PHASE1/PHASE2 | RECRUITING | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma |
| NCT04594798 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL |
| NCT04665765 | PHASE2 | ACTIVE_NOT_RECRUITING | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| NCT04679012 | PHASE2 | RECRUITING | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter’s Transformation |
| NCT04913103 | PHASE2 | NOT_YET_RECRUITING | Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL |
| NCT04914741 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) |
| NCT05283720 | PHASE2 | RECRUITING | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma |
| NCT05410418 | PHASE2 | ACTIVE_NOT_RECRUITING | Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma |
| NCT05455697 | PHASE1/PHASE2 | RECRUITING | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma |
| NCT05615636 | PHASE2 | RECRUITING | A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL |
| NCT05633615 | PHASE2 | RECRUITING | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| NCT05798156 | PHASE2 | ACTIVE_NOT_RECRUITING | Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP |
| NCT06040320 | PHASE1/PHASE2 | RECRUITING | Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) |
| NCT06043674 | PHASE2 | RECRUITING | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter’s Transformation |
| NCT06071871 | PHASE2 | RECRUITING | A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma |
| NCT06176729 | PHASE2 | RECRUITING | Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients |
| NCT06441097 | PHASE2 | NOT_YET_RECRUITING | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL |
| NCT06453044 | PHASE2 | RECRUITING | Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma |
| NCT06468943 | PHASE2 | ENROLLING_BY_INVITATION | Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL |
| NCT06516978 | PHASE2 | NOT_YET_RECRUITING | A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL |
| NCT06530511 | PHASE2 | RECRUITING | Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL |
| NCT06554600 | PHASE2 | RECRUITING | A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| NCT06594939 | PHASE2 | NOT_YET_RECRUITING | Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma |
| NCT06803693 | PHASE2 | RECRUITING | Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL |
| NCT06890884 | PHASE2 | RECRUITING | A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) |
| NCT07012980 | PHASE2 | NOT_YET_RECRUITING | Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL |
| NCT07034508 | PHASE2 | NOT_YET_RECRUITING | A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 |
| NCT07122609 | PHASE2 | NOT_YET_RECRUITING | Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| NCT07397832 | PHASE2 | RECRUITING | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL |
| NCT07415980 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL |
| NCT07502872 | PHASE2 | NOT_YET_RECRUITING | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).